Cardiotonic Steroids-Mediated Na⁺/K⁺-ATPase Targeting Could Circumvent Various Chemoresistance Pathways

Abstract

Many cancer patients fail to respond to chemotherapy because of the intrinsic resistance of their cancer to pro-apoptotic stimuli or the acquisition of the multidrug resistant phenotype during chronic treatment. Previous data from our groups and from others point to the sodium/potassium pump (the Na⁺/K⁺-ATPase, i.e., NaK) with its highly specific ligands (i.e., cardiotonic steroids) as a new target for combating cancers associated with dismal prognoses, including gliomas, melanomas, non-small cell lung cancers, renal cell carcinomas, and colon cancers. Cardiotonic steroid-mediated Na⁺/K⁺-ATPase targeting could circumvent various resistance pathways. The most probable pathways include the involvement of Na⁺/K⁺-ATPase β subunits in invasion features and Na⁺/K⁺-ATPase α subunits in chemosensitisation by specific cardiotonic steroid-mediated apoptosis and anoïkis-sensitisation; the regulation of the expression of multidrug resistant-related genes; post-translational regulation, including glycosylation and ubiquitinylation of multidrug resistant-related proteins; c-Myc downregulation; hypoxia-inducible factor downregulation; NF-κB downregulation and deactivation; the inhibition of the glycolytic pathway with a reduction of intra-cellular ATP levels and an induction of non-apoptotic cell death. The aims of this review are to examine the various molecular pathways by which the NaK targeting can be more deleterious to biologically aggressive cancer cells than to normal cells.

Key words

Na⁺/K⁺-ATPase - sodium pump - cardiotonic steroids - cardenolide - bufadienolide - cancer chemoresistance - multidrug resistance

^* R. K. is a Director of Research of the Fonds National de la Recherche Scientifique (FNRS; Brussels, Belgium).

• References

• 1 Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-292
• 2 Ricci MS, Zong WX. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 2006; 11: 342-357
• 3 Pommier Y, Sorde O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004; 23: 2934-2949
• 4 Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006; 13: 1859-1876
• 5 Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-234
• 6 Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008; 15: 1981-2039
• 7 Steiner E, Holzmann K, Elbling L, Micksche M, Berger W. Cellular functions of vaults and their involvement in multidrug resistance. Curr Drug Targets 2006; 7: 923-934
• 8 Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006; 7: 861-879
• 9 Horisberger JD. Recent insights into the structure and mechanism of the sodium pump. Physiology (Bethesda) 2004; 19: 377-387
• 10 Rajasekaran SA, Palmer LG, Quan K, Harper JF, Ball Jr WJ, Bander NH, Peralta Soler A, Rajasekaran AK. Na,K-ATPase beta subunit is required for epithelial polarization, suppression of invasion, and cell motility. Mol Biol Cell 2001; 12: 279-295
• 11 Rajasekaran AK, Rajasekaran SA. Role of Na-K-ATPase in the assembly of tight junctions. Am J Physiol Renal Physiol 2003; 285: F388-F396
• 12 Contreras RG, Shoshani L, Flores-Maldonado C, Lázaro A, Cereijido M. Relationship between Na(+),K(+)-ATPase and cell attachment. J Cell Sci 1999; 112: 4223-4232
• 13 Cereijido M, Shoshani L, Contreras RG. The polarized distribution of Na+, K+-ATPase and active transport across epithelia. J Membr Biol 2001; 184: 299-304
• 14 Contreras RG, Flores-Maldonado C, Lázaro A, Shoshani L, Flores-Benitez D, Larré I, Cereijido M. Ouabain binding to Na+,K+-ATPase relaxes cell attachment and sends a specific signal (NACos) to the nucleus. J Membr Biol 2004; 198: 147-158
• 15 Shoshani L, Contreras RG, Roldán ML, Moreno J, Lázaro A, Balda MS, Matter K, Cereijido M. The polarized expression of Na+,K+-ATPase in epithelia depends on the association between beta subunits located in neighboring cells. Mol Biol Cell 2005; 16: 1071-1081
• 16 Larre I, Ponce A, Fiorentino R, Shoshani L, Contreras RG, Cereijido M. Contacts and cooperation between cells depend on the hormone ouabain. Proc Natl Acad Sci USA 2006; 103: 10911-10916
• 17 Rajasekaran SA, Beyenbach KW, Rajasekaran AK. Interactions of tight junctions with membrane channels and transporters. Biochim Biophys Acta 2008; 1778: 757-769
• 18 Cereijido M, Contreras RG, Shoshani L, Flores-Benitez D, Larre I. Tight junction and polarity interaction in the transporting epithelial phenotype. Biochim Biophys Acta 2008; 1778: 770-793
• 19 Xie Z, Askari A. Na(⁺)/K(⁺)-ATPase as a signal transducer. Eur J Biochem 2002; 269: 2434-2439
• 20 Xie Z, Cai T. Na⁺-K⁺-ATPase-mediated signal transduction: from protein interaction to cellular function. Mol Interv 2003; 3: 157-168
• 21 Pierre SV, Xie Z. The NaK-ATPase receptor complex: its organization and membership. Cell Biochem Biophys 2006; 46: 303-316
• 22 Liang M, Cai T, Tian J, Qu W, Xie ZJ. Functional characterization of Src-interacting Na/K-ATPase using RNA interference assay. J Biol Chem 2006; 281: 19709-19719
• 23 Liang M, Tian J, Liu L, Pierre S, Liu J, Shapiro J, Xie ZJ. Identification of a pool of non-pumping Na/K-ATPase. J Biol Chem 2007; 282: 10585-10593
• 24 Wang H, Haas M, Liang M, Cai T, Tian J, Li S, Xie Z. Ouabain assembles signaling cascades through the caveolar Na⁺/K⁺-ATPase. J Biol Chem 2004; 279: 17250-17259
• 25 Liu L, Ivanov AV, Gable ME, Jolivel F, Morrill GA, Askari A. Comparative properties of caveolar and noncaveolar preparations of kidney Na(+)/K(+)-ATPase. Biochemistry 2011; 50: 8664-8673
• 26 Prassas I, Karagiannis GS, Batruch I, Dimitromanolakis A, Datti A, Diamandis EP. Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks. Mol Cancer Ther 2011; 10: 2083-2093
• 27 Mijatovic T, Van Quaquebeke E, Delest B, Debeir O, Darro F, Kiss R. Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta 2007; 1776: 32-57
• 28 Espineda C, Chang JH, Twis J, Rajasekaran SA, Rajasekaran AK. Repression of NaK-ATPase β1 subunit by the transcription factor Snail in carcinoma. Mol Biol Cell 2004; 15: 1364-1373
• 29 Blok LJ, Chang GT, Steenbeek-Slotboom M, van Weerden WM, Swarts HG, De Pont JJ, van Steenbrugge GJ, Brinkmann AO. Regulation of expression of Na⁺K⁺-ATPase in androgen-dependent and androgen-independent prostate cancer. Br J Cancer 1999; 81: 28-36
• 30 Akopyanz NS, Broude NE, Bekman EP, Marzen EO, Sverdlov ED. Tissue-specific expression of NaK-ATPase beta subunit. Does beta 2 expression correlate with tumorigenesis?. FEBS Lett 1991; 289: 8-10
• 31 Boukerche H, Su ZZ, Kang DC, Fisher PB. Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridization. Gene 2004; 343: 191-201
• 32 Sakai H, Suzuki T, Maeda M, Takahashi Y, Horikawa N, Minamimura T, Tsukada K, Takeguchi N. Up-regulation of Na(⁺)K(⁺)-ATPase alpha 3-isoform and downregulation of the alpha 1-isoform in human colorectal cancer. FEBS Lett 2004; 563: 151-154
• 33 Rajasekaran SA, Ball Jr WJ, Bander NH, Liu H, Pardee JD, Rajasekaran AK. Reduced expression of beta subunit of NaK-ATPase in human clear-cell renal cell carcinoma. J Urol 1999; 62: 574-580
• 34 Lefranc F, Mijatovic T, Kondo Y, Sauvage S, Roland I, Debeir O, Krstic D, Vasic V, Gailly P, Kondo S, Blanco G, Kiss R. Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery 2008; 62: 211-221
• 35 Mijatovic T, Roland I, Van Quaquebeke E, Nilsson B, Mathieu A, Van Vynckt F, Darro F, Blanco G, Facchini V, Kiss R. The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J Pathol 2007; 212: 170-179
• 36 Seligson DB, Rajasekaran SA, Yu H, Liu X, Eeva M, Tze S, Ball Jr WJ, Horvath S, deKernion JB, Rajasekaran AK. NaK-adenosine triphosphatase alpha1 subunit predicts survival of renal clear cell carcinoma. J Urol 2008; 179: 338-345
• 37 Mijatovic T, Ingrassia L, Facchini V, Kiss R. Na+/K+-ATPase alpha subunits as new targets in anticancer therapy. Expert Opin Ther Targets 2008; 12: 1403-1417
• 38 Mathieu V, Pirker C, Martin de Lassalle E, Vernier M, Mijatovic T, De Neve N, Gaussin JF, Dehoux M, Lefranc F, Berger W, Kiss R. The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med 2009; 13: 3960-3972
• 39 Mijatovic T, Dufrasne F, Kiss R. Na+/K+-ATPase and cancer. Pharmaceutical Patent Analyst 2012; 1: 91-106
• 40 Gheorghiade M, Adams Jr KF, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation 2004; 109: 2959-2964
• 41 Stenkvist B. Cardenolides and cancer. Anticancer Drugs 2001; 12: 635-636
• 42 Johnson PH, Walker RP, Jones SW, Stephens K, Meurer J, Zajchowski DA, Luke MM, Eeckman F, Tan Y, Wong L, Parry G, Morgan Jr. TK, McCarrick MA, Monforte J. Multiplex gene expression analysis for high-throughput drug discovery: screening and analysis of compounds affecting genes overexpressed in cancer cells. Mol Cancer Ther 2002; 1: 1293-1304
• 43 Lindholm P, Gullbo J, Claeson P, Göransson U, Johansson S, Backlund A, Larsson R, Bohlin L. Selective cytotoxicity evaluation in anticancer drug screening of fractionated plant extracts. J Biomol Screen 2002; 7: 333-340
• 44 Mijatovic T, Lefranc F, Van Quaquebeke E, Van Vynckt F, Darro F, Kiss R. UNBS1450: A new hemi-synthetic cardenolide with promising anti-cancer activity. Drug Dev Res 2007; 68: 164-173
• 45 Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 2008; 8: 36-49
• 46 Gao H, Popescu R, Kopp B, Wang Z. Bufadienolides and their antitumor activity. Nat Prod Rep 2011; 28: 953-969
• 47 Mijatovic T, Dufrasne F, Kiss R. Cardiotonic steroidsʼ-mediated targeting of the Na⁺/K⁺-ATPase to combat chemoresistant cancers. Curr Med Chem 2012; 19: 627-646
• 48 Cerella C, Dicato M, Diederich M. Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosides. Mitochondrion advance online publication 24.06.2012; DOI: 10.1016/j.mito.2012.06.003.
• 49 Van Quaquebeke E, Simon G, Andre A, Dewelle J, El Yazidi M, Bruyneel F, Tuti J, Nacoulma O, Guissou P, Decaestecker C, Braekman JC, Kiss R, Darro F. Identification of a novel cardenolide (2′′-oxovorusharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: Structure-activity relationship analyses. J Med Chem 2005; 48: 849-856
• 50 Lefranc F, Kiss R. The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia 2008; 10: 198-206
• 51 Mijatovic T, Op De Beek A, Van Quaquebeke E, Dewelle J, Darro F, de Launoit Y, Kiss R. The cardenolide UNBS1450 is able to deactivate NF-kB-mediated cytoprotective effects in human non-small-cell-lung cancer (NSCLC) cells. Mol Cancer Ther 2006; 5: 391-399
• 52 Mijatovic T, Jungwirth U, Heffeter P, Hoda MA, Dornetshuber R, Kiss R, Berger W. The Na+/K+-ATPase is the Achilles heel of multi-drug-resistant cancer cells. Cancer Lett 2009; 282: 30-34
• 53 Piacente S, Masullo M, De Nève N, Dewelle J, Hamed A, Kiss R, Mijatovic T. Cardenolides from Pergularia tomentosa display cytotoxic activity resulting from their potent inhibition of Na+/K+-ATPase. J Nat Prod 2009; 72: 1087-1091
• 54 Zhao M, Bai L, Wang L, Toki A, Hasegawa T, Kikuchi M, Abe M, Sakai J, Hasegawa R, Bai Y, Mitsui T, Ogura H, Kataoka T, Oka S, Tsushima H, Kiuchi M, Hirose K, Tomida A, Tsuruo T, Ando M. Bioactive cardenolides from the stems and twigs of Nerium oleander. J Nat Prod 2007; 70: 1098-1103
• 55 Tummala R, Wolle D, Barwe SP, Sampson VB, Rajasekaran AK, Pendyala L. Expression of NaK-ATPase-beta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin. Cancer Chemother Pharmacol 2009; 64: 1187-1194
• 56 Rajasekaran SA, Barwe SP, Rajasekaran AK. Multiple functions of NaK-ATPase in epithelial cells. Semin Nephrol 2005; 25: 328-334
• 57 Espineda C, Seligson DB, Ball Jr. JW, Rao J, Palotie A, Horvath S, Huang Y, Shi T, Rajasekaran AK. Analysis of the Na/K-ATPase alpha- and beta subunit expression profiles of bladder cancer using tissue microarrays. Cancer 2003; 97: 1859-1868
• 58 Yoshimura SH, Iwasaka S, Schwarz W, Takeyasu K. Fast degradation of the auxiliary subunit of Na+/K+-ATPase in the plasma membrane of HeLa cells. J Cell Sci 2008; 121: 2159-2168
• 59 Mijatovic T, Mathieu V, Gaussin JF, De Nève N, Ribaucour F, Van Quaquebeke E, Dumont P, Darro F, Kiss R. Cardenolide-induced lysosomal membrane permeabilization contributes therapeutic benefits in experimental human non-small-cell-lung cancers. Neoplasia 2006; 8: 402-412
• 60 Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA. Cardiac glycosides initiate Apo2 L/TRAIL-induced apoptosis in non-small cell lung cancer cells by upregulation of death receptors 4 and 5. Cancer Res 2006; 66: 5867-5874
• 61 McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA. Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent metastatic human prostate adenocarcinoma cells. Cancer Res 2000; 60: 3807-3812
• 62 Sreenivasan Y, Raghavendra PB, Manna SK. Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells. J Clin Immunol 2006; 26: 308-322
• 63 Dong Y, Yin S, Li J, Jiang C, Ye M, Hu H. Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway. Apoptosis 2011; 16: 394-403
• 64 Simpson CD, Mawji IA, Anyiwe K, Williams MA, Wang X, Venugopal AL, Gronda M, Hurren R, Cheng S, Serra S, Beheshti Zavareh R, Datti A, Wrana JL, Ezzat S, Schimmer AD. Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. Cancer Res 2009; 69: 2739-2747
• 65 Newman RA, Kondo Y, Yokoyama T, Dixon S, Cartwright C, Chan D, Johansen M, Yang P. Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Integr Cancer Ther 2007; 6: 354-364
• 66 Takara K, Takagi K, Tsujimoto M, Ohnishi N, Yokoyama T. Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun 2003; 306: 116-120
• 67 Huang DM, Guh JH, Huang YT, Chueh SC, Wang HP, Teng CM. Cardiac glycosides induce resistance to tubulin-dependent anti-cancer drugs in androgen-independent human prostate cancer. J Biomed Sci 2002; 9: 443-452
• 68 Lawrence TS, Davis MA. The influence of Na⁺K⁺-pump blockade on doxorubicin-mediated cytotoxicity and DNA strand breakage in human tumor cells. Cancer Chemother Pharmacol 1990; 26: 163-167
• 69 Ahmed Z, Deyama Y, Yoshimura Y, Suzuki K. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na⁽⁺⁾K⁽⁺⁾-ATPase activity rather than copper-transporting P-type ATPases ATP7A and ATP7B. Cancer Chemother Pharmacol 2009; 63: 643-650
• 70 Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 2002; 28: 160-168
• 71 Melero CP, Medarde M, San Feliciano A. A short review on cardiotonic steroids and their aminoguanidine analogues. Molecules 2000; 5: 51-81
• 72 Steyn PS, van Heerden FR. Bufadienolides of plant and animal origin. Nat Prod Rep 1998; 15: 397-413
• 73 Roy MC, Chang FR, Huang HC, Chiang MY, Wu YC. Cytotoxic principles from the formosan milkweed Asclepias curassavica . J Nat Prod 2005; 68: 1494-1499
• 74 Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Update 2011; 14: 191-201
• 75 Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 2008; 105: 19579-19586
• 76 Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004; 6: 203-208
• 77 Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107: 241-246
• 78 Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297-309
• 79 Srivastava M, Eidelman O, Zhang J, Paweletz C, Caohuy H, Yang Q, Jacobson KA, Heldman E, Huang W, Jozwik C, Pollard BS, Pollard HB. Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proc Natl Acad Sci USA 2004; 101: 7693-7698
• 80 Manna SK, Sah NK, Newman RA, Cisneros A, Aggarwal BB. Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-jun NH₂-terminal kinase. Cancer Res 2000; 60: 3838-3847
• 81 Aizman O, Uhlen P, Lal M, Brismar H, Aperia A. Ouabain, a steroid hormone that signals with slow calcium oscillations. Proc Natl Acad Sci USA 2001; 98: 13420-13424
• 82 McDevitt CA, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors?. Pharmacol Ther 2007; 113: 429-441
• 83 Schinkel AH, Kemp S, Dollé M, Rudenko G, Wagenaar E. N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem 1993; 268: 7474-7481
• 84 Kramer R, Weber TK, Arceci R, Ramchurren N, Kastrinakis WV, Steele Jr. G, Summerhayes IC. Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. Br J Cancer 1995; 71: 670-675
• 85 Beheshti Zavareh R, Lau KS, Hurren R, Datti A, Ashline DJ, Gronda M, Cheung P, Simpson CD, Liu W, Wasylishen AR, Boutros PC, Shi H, Vengopal A, Jurisica I, Penn LZ, Reinhold VN, Ezzat S, Wrana J, Rose DR, Schachter H, Dennis JW, Schimmer AD. Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. Cancer Res 2008; 68: 6688-6697
• 86 Zhang Z, Wu JY, Hait WN, Yang JM. Regulation of the stability of P-glycoprotein by ubiquitination. Mol Pharmacol 2004; 66: 395-403
• 87 Bentley J, Bell SE, Quinn DM, Kellett GL, Warr JR. 2-Deoxy-D-glucose toxicity and transport in human multidrug-resistant KB carcinoma cell lines. Oncol Res 1996; 8: 77-84
• 88 Lyon RC, Cohen JS, Faustino PJ, Megnin F, Myers CE. Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. Cancer Res 1988; 48: 870-877
• 89 Sharom FJ, Yu X, Chu JW, Doige CA. Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochem J 1995; 308: 381-390
• 90 Mijatovic T, De Nève N, Gailly P, Mathieu V, Haibe-Kains B, Bontempi G, Lapeira J, Decaestecker C, Facchini V, Kiss R. Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity. Mol Cancer Ther 2008; 7: 1285-1296
• 91 López-Lázaro M. Digitoxin as an anti-cancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opin Ther Targets 2007; 11: 1043-1053
• 92 Brouillard F, Tondelier D, Edelman A, Baudouin-Legros M. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells. Cancer Res 2001; 61: 1693-1698
• 93 Dvela M, Rosen H, Feldmann T, Nesher M, Lichtstein D. Diverse biological responses to different cardiotonic steroids. Pathophysiology 2007; 14: 159-166
• 94 Chen Y, Bathula SR, Li J, Huang L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 2010; 285: 22639-22650
• 95 Nakamura Y, Sato H, Motokura T. Development of multidrug resistance due to multiple factors including P-glycoprotein overexpression under K-selection after MYC and HRAS oncogene activation. Int J Cancer 2006; 118: 2448-2454
• 96 Grandjean-Forestier F, Stenger C, Robert J, Verdier M, Ratinaud MH. The P-glycoprotein 170: Just a multidrug resistance protein or a protean molecule?. In: Boumendjel A, Boutonnat J, Robert J, Wang B, editors ABC transporters and multidrug resistance. New York: Wiley-Liss; 2009: 17-26
• 97 Mijatovic T, De Nève N, Mathieu V, Kiss R. c-Myc downregulation as a surrogate marker of cardenolide-induced anti-tumor activity. San Diego, CA: 99th American Association for Cancer Research (AACR) Annual Meeting, San Diego; 2008
• 98 Arabi A, Wu S, Ridderstrale K, Bierhoff H, Shiue C, Fatyol K, Fahlén S, Hydbring P, Söderberg O, Grummt I, Larsson LG, Wright AP. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol 2005; 7: 303-310
• 99 Grandori C, Gomez-Roman N, Felton-Edkin ZA, Ngouenet C, Galloway DA, Eisenman RN, White RJ. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol 2005; 7: 311-318
• 100 Tong X, Zhao F, Thompson CB. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev 2009; 19: 32-37
• 101 Ponzielli R, Katz S, Barsyte-Lovejoy D, Penn LZ. Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 2005; 41: 2485-2501
• 102 Chou WC, Chen HY, Yu SL, Cheng L, Yang PC, Dang CV. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood 2005; 106: 304-310
• 103 Gasper R, Mijatovic T, Bénard A, Derenne A, Kiss R, Goormaghtigh E. FTIR spectral signature of the effect of cardiotonic steroids with antitumoral properties on a prostate cancer cell line. Biochim Biophys Acta 2010; 1802: 1087-1094
• 104 Akimova OA, Hamet P, Orlov SN. [Na⁺]i/[K⁺]i-independent death of ouabain-treated renal epithelial cells is not mediated by Na⁺K⁺-ATPase internalization and de novo gene expression. Pflugers Arch 2008; 455: 711-719
• 105 Liu J, Kesiry R, Periyasamy SM, Malhotra D, Xie Z, Shapiro JI. Ouabain induces endocytosis of plasmalemmal Na/K-ATPase in LLC-PK1 cells by a clathrin-dependent mechanism. Kidney Int 2004; 66: 227-241
• 106 Pierre SV, Sottejeau Y, Gourbeau JM, Sánchez G, Shidyak A, Blanco G. Isoform specificity of Na-K-ATPase-mediated ouabain signaling. Am J Physiol Renal Physiol 2008; 294: F859-866
• 107 Katz A, Lifshitz Y, Bab-Dinitz E, Kapri-Pardes E, Goldshleger R, Tal DM, Karlish SJ. Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase. J Biol Chem 2010; 285: 19582-19592
• 108 Crambert G, Hasler U, Beggah AT, Yu C, Modyanov NN, Horisberger JD, Lelievre L, Geering K. Transport and pharmacological properties of nine different human Na K-ATPase isozymes. J Biol Chem 2000; 275: 1976-1986
• 109 Blanco G. NaK-ATPase subunit heterogeneity as a mechanism for tissue-specific ion regulation. Semin Nephrol 2005; 25: 292-303
• 110 Blanco G. The Na/K-ATPase and its isozymes: what we have learned using the baculovirus expression system. Front Biosci 2005; 10: 2397-2411
• 111 Keenan SM, De Lisle RK, Welsh WJ, Paula S, Ball Jr. WJ. Elucidation of the Na+K+-ATPase digitalis binding site. J Mol Graphics Model 2005; 23: 465-475
• 112 Sharabani-Yosef O, Bak A, Langzam L, Lui Z, Nir U, Braiman L, Sweadner KJ, Sampson SR. Rat skeletal muscle in culture expresses the alpha1 but not the alpha2 protein subunit isoform of the Na⁺/K⁺ pump. J Cell Physiol 1999; 180: 236-244
• 113 Arystarkhova E, Sweadner KJ. Hormonal and neurogenic control of Na-K-ATPase and myosin isoforms in neonatal rat cardiac myocytes. Am J Physiol 1997; 273: C489-499
• 114 Perne A, Muellner MK, Steinrueck M, Craig-Mueller N, Mayerhofer J, Schwarzinger I, Sloane M, Uras IZ, Hoermann G, Nijman SM, Mayerhofer M. Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PLoS One 2009; 4: e8292
• 115 Hallböök H, Felth J, Eriksson A, Fryknäs M, Bohlin L, Larsson R, Gullbo J. Ex vivo activity of cardiac glycosides in acute leukaemia. PLoS One 2011; 6: e15718
• 116 Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E, Nelson WG. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov 2011; 1: 68-77
• 117 Stenkvist B. Is digitalis a therapy for breast carcinoma?. Oncol Rep 1999; 6: 493-496
• 118 Biggar RJ, Wohlfahrt J, Oudin A, Hjuler T, Melbye M. Digoxin use and the risk of breast cancer in women. J Clin Oncol 2011; 29: 2165-2170
• 119 Bidyasar S, Kurzrock R, Falchook GS, Naing A, Wheler JJ, Durand J, Yang P, Johansen MJ, Newman RA, Khan R, Hong D. A first-in-human phase I trial of PBI-05204 (oleandrin), an inhibitor of Akt, FGF-2, NF-Kb, and p 70S6K in advanced solid tumor patients. J Clin Oncol 2009; 27 15S: 3537